Skip to main content
. Author manuscript; available in PMC: 2007 Jul 17.
Published in final edited form as: J Immunol. 2005 May 15;174(10):5994–6004. doi: 10.4049/jimmunol.174.10.5994

Figure 7. Tumor therapy with CEA/TRICOM vaccine, GM-CSF and anti-CTLA-4 mAb.

Figure 7

CEA-Tg mice (n=10/group) were transplanted s.c. with MC38-CEA+ tumors on day 0. Four days later, mice received rV-CEA/TRICOM prime vaccination admixed with rF-GM-CSF and were administered anti-CTLA-4 mAb, followed by three weekly boosts with rF-CEA/TRICOM admixed with rF-GM-CSF (closed circles). Another group of CEA-Tg mice received rV-CEA/TRICOM prime vaccination admixed with rF-GM-CSF followed by three weekly boosts with rF-CEA/TRICOM admixed with rF-GM-CSF (closed triangles). Another group of mice received anti-CTLA-4 mAb alone (closed diamonds). A control group received buffer (HBSS, open squares). Mice in each group were monitored weekly for tumor size and survival. Inset panel: Tumor volumes ≤ 400 mm3.